Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-MeO-DMT IV Infusions in Healthy Participants
NCT07444788Phase 1Recruiting
- Sponsor
- University Hospital Basel
- Start
- Aug 2026
- Primary completion
- Mar 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 5-MeO-DMT in major depressive disorder (MDD) (5 arms), sponsored by University Hospital Basel. Primary endpoint: Subjective Effect Scales up to 245 minutes. Started Aug 2026; status: recruiting.
02
Drugs
5-MeO-DMT
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07444788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444788.